4.7 Article

Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease

Journal

NEUROBIOLOGY OF DISEASE
Volume 117, Issue -, Pages 125-136

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2018.05.021

Keywords

Cholinergic basal forebrain; Mild cognitive impairment; Nucleus basalis of Meynert; Trk receptor; Neurotrophin; Acetylcholine receptor; Glutamate receptor; Dopamine receptor; Adrenoceptor; Neurotransmission

Categories

Funding

  1. NIH [AG014449, AG053581, AG053760, NS082730, AG044372, AG043375, AG107617, AG19610]
  2. Alzheimer's Association [IIRG-11203928]
  3. Thorek Memorial Foundation
  4. Saint Mary's Foundation
  5. Miles for Memories of Battle Creek, MI
  6. Barrow Neurological Institute Barrow and Beyond

Ask authors/readers for more resources

Cholinergic basal forebrain neurons of the nucleus basalis of Meynert (nbM) regulate attentional and memory function and are exquisitely prone to tau pathology and neurofibrillary tangle (NFT) formation during the progression of Alzheimer's disease (AD). nbM neurons require the neurotrophin nerve growth factor (NGF), its cognate receptor TrkA, and the pan-neurotrophin receptor p75(NTR) for their maintenance and survival. Additionally, nbM neuronal activity and cholinergic tone are regulated by the expression of nicotinic (nAChR) and muscarinic (mAChR) acetylcholine receptors as well as receptors modulating glutamatergic and catecholaminergic afferent signaling. To date, the molecular and cellular relationships between the evolution of tau pathology and nbM neuronal survival remain unknown. To address this knowledge gap, we profiled cholinotrophic pathway genes within nbM neurons immunostained for pS422, a pretangle phosphorylation event preceding tau C-terminal truncation at D421, or dual-labeled for pS422 and TauC3, a later stage tau neo-epitope revealed by this same C-terminal truncation event, via single-population custom microarray analysis. nbM neurons were obtained from postmortem tissues from subjects who died with an antemortem clinical diagnosis of no cognitive impairment (NCI), mild cognitive impairment (MCI), or mild/moderate AD. Quantitative analysis revealed significant downregulation of mRNAs encoding TrkA as well as TrkB, TrkC, and the Trk-mediated downstream pro-survival kinase Akt in pS422 + compared to unlabeled, pS422-negative nbM neurons. In addition, pS422 + neurons displayed a downregulation of transcripts encoding NMDA receptor subunit 2B, metabotropic glutamate receptor 2, D2 dopamine receptor, and 131 adrenoceptor. By contrast, transcripts encoding p75(NTR) were downregulated in dual-labeled pS422 + /TauC3 + neurons. Appearance of the TauC3 epitope was also associated with an upregulation of the alpha 7 nAChR subunit and differential downregulation of the beta 2 nAChR subunit. Notably, we found that gene expression patterns for each cell phenotype did not differ with clinical diagnosis. However, linear regression revealed that global cognition and Braak stage were predictors of select transcript changes within both unlabeled and pS422 + /TauC3 - neurons. Taken together, these cell phenotype specific gene expression profiling data suggest that dysregulation of neurotrophic and neurotransmitter signaling is an early pathogenic mechanism associated with NFT formation in vulnerable nbM neurons and cognitive decline in AD, which may be amenable to therapeutic intervention early in the disease process.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available